Navigation Links
New treatment for age-related macular degeneration within sight
Date:11/29/2007

With 8 million people at high risk for advanced age-related macular degeneration, researchers from Harvard and Japan discovered that the experimental drug, endostatin, may be the cure. A research report published in the December 2007 issue of The FASEB Journal, describes how giving endostatin to mice significantly reduced or eliminated abnormal blood vessel growth within the eye, which is ultimately why the disease causes blindness.

Our study provides intriguing findings that may lead to a better treatment of age-related macular degeneration, said Alexander Marneros, the first author of the report, but clinical studies in patients with age-related macular degeneration are still necessary.

In this study, researchers describe testing the effects of endostatin on mice lacking this naturally occurring substance. The mice without endostatin were about three times more likely to develop advanced age-related macular degeneration (AMD) than normal mice. Then the researchers administered endostatin to both sets of mice. In the mice lacking endostatin, the number of abnormal blood vessels that cause AMD were reduced to normal levels. In control mice with normal levels of endostatin, the number of abnormal blood vessels were practically undetectable.

With Baby Boomers reaching advanced ages, new treatments are desperately needed to keep age-related macular degeneration from becoming a national epidemic, said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. This research provides hope for those at risk for blindness, and it gives everyone another glimpse of how investments in molecular biology will ultimately pay off in terms of new treatments and cures.

AMD is a progressive disease that affects the part of the eye that allows people to see fine details. The disease gradually destroys sharp, central vision, and in advanced stages ultimately leads to total blindness. Abnormal blood vessel growth, also known as angiogenesis, i
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... German . The ... threats to health, and to provide life-long memory that ... underlying immunologic memory, however, has remained elusive. Since 2001, ... hypothesis that the persistence of immune memory arises from ... now, there was no conclusive evidence, largely because experiments ...
(Date:7/23/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing ... common stock at a price to the public of $6.00 ... 30-day option to purchase up to 1,250,000 additional shares of ... are expected to begin trading on the NYSE MKT on ... William Blair & Company, L.L.C. and JMP Securities LLC ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3Pfenex Inc. Announces Pricing Of Initial Public Offering 2
... Dr. Shirley Tilghman and colleagues (Princeton University) lend new ... necessary role for a non-coding RNA transcript in the ... Imprinting, or the differential expression of a gene based ... integral to normal growth and development. Two human disorders, ...
... of predicting air pollution don't take atmospheric chlorine into ... percent or more of daily ozone production in local ... measurements taken nearly nonstop in the Irvine area over ... typically measured five parts per trillion or less, but ...
... Iron and Zinc commonly limit plant growth and crop ... to better understand the mechanisms of micronutrient uptake, distribution ... it feasible to engineer nutrient-rich plants better able to ... crop biomass in soils now in cultivation. Guerinot presented ...
Cached Biology News:UCI scientists find chlorine may contribute to ozone formation 2Metal homeostasis research in plants will lead to nutrient-rich food and higher yielding crops 2
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a ... the long term. They are the first functional focus ... energy as an alternative to the temporary fix associated ... Indiegogo on July 29, 2014, with hopes to raise ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
Breaking Biology Technology:Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
... Patients Worldwide, FERNDALE, Michigan and NESS ZIONA, ... Ltd. announced today that the two,companies executed a ... foam for the treatment of atopic dermatitis and,eczema., ... development of,non-steroidal foam which is designed to help ...
... Periodontal Inflammation and ... Gene-Environment Interactions, WALTHAM, Mass., June 3 ... Dr. Kenneth Kornman, Chief,Scientific Officer, will present at the 13th ... Ljubljana, Slovenia on the,genetic and environmental factors that control inflammation ...
Cached Biology Technology:Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis 2Interleukin Genetics to Present at the 13th International Conference on Periodontal Research 2Interleukin Genetics to Present at the 13th International Conference on Periodontal Research 3
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... performance spectral scanning multimode reader with ... advanced SkanIt Software it offers superior ... assay development. Varioskan provides unlimited wavelength ... and photometric assays and a dispenser ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: